Chemomab Therapeutics (CMMB) Market Capitalization (2021 - 2026)

Chemomab Therapeutics (CMMB) has reported Market Capitalization for 6 consecutive years, with $11.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 46.73% year-over-year to $11.7 million; the trailing twelve-month figure through Jun 2026 stood at $11.7 million (down 46.73% YoY), and the FY2025 full-year result was $11.9 million, down 65.23% from the prior year.
• Market Capitalization grew to $11.7 million in Q2 2026 per CMMB's latest filing, from $11.3 million in the prior quarter.
• Across five years, Market Capitalization topped out at $54.7 million in Q1 2022 and bottomed at $6.0 million in Q4 2023.
• Historically, Market Capitalization has averaged $20.8 million across 5 years, with a median of $16.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Market Capitalization slumped 83.9% in 2023, then soared 469.56% in 2024.
• Over 5 years, Market Capitalization stood at $37.2 million in 2022, then plunged by 83.9% to $6.0 million in 2023, then jumped by 469.56% to $34.1 million in 2024, then slumped by 65.23% to $11.9 million in 2025, then decreased by 1.82% to $11.7 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $11.7 million, $11.3 million, and $11.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.